Serious infections were uncommon among patients with psoriatic arthritis exposed to targeted therapies for the first time in “a large and exhaustive” French cohort, according to data published in RMD Open.Compared with new users of adalimumab (Humira, Abbvie), risk for serious infection was significantly lower among new users of etanercept (Enbrel, Immunex) and ustekinumab (Stelara,
Cosmo Pharmaceuticals (OTC:CMOPF – Get Free Report) and AbbVie (NYSE:ABBV – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, dividends, earnings and risk. Insider and Institutional Ownership 70.2% of AbbVie shares are […]
Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) saw a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 8,990,000 shares, a drop of 17.7% from the April 30th total of 10,920,000 shares. Based on an average trading volume of 2,150,000 shares, the days-to-cover ratio […]
Quadruple Therapies Including Immunotherapy Agents Show Benefit in Multiple Myeloma pharmacytimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmacytimes.com Daily Mail and Mail on Sunday newspapers.